Immune Checkpoint Inhibitor Is Associated with Improved Survival in Advanced Non-small Cell Lung Cancer Occurring in Patients with Autoimmune Disease

In conclusion, our study showed comparable associations between ICI therapy and reduced mortality in AD and non-AD subgroups of patients with advanced NSCLC. However, therapy strategies tailored to each AD type and thorough discussions regarding the risk-benefit profile are crucial.PMID:38382998 | DOI:10.1248/bpb.b23-00713

Source: Biological and Pharmaceutical Bulletin - February 21, 2024 Category: Drugs & Pharmacology Authors: Yasutaka Ihara Kenji Sawa Takumi Imai Yuta Nonomiya Yuki Shimomura Asahi Ishihara Ayumi Shintani Source Type: research